CNS

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on: 
Monday, March 25, 2024
Central nervous system, District court, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Action Replay, Excellence, FDA, Central nervous system disease, Court, Advertising

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Neurology, Week, Narcolepsy, Somnolence, Memory, Cataplexy, Central nervous system, Patient, CNS, Montefiore Medical Center, EDS, Concentrate, SYMPHONY, Epworth Sleepiness Scale, Quality of life, Therapy, Cognition, Concurrency, ESS, Reboxetine, Pharmaceutical industry

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.

Key Points: 
  • AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.
  • SYMPHONY was a Phase 3 multicenter, randomized, double-blind, placebo-controlled trial in which 90 patients with a diagnosis of narcolepsy with cataplexy were randomized to treatment with AXS-12 or placebo for 5 weeks.
  • “The SYMPHONY Phase 3 trial results confirm the promise and potential of AXS-12 for the treatment of narcolepsy,” said Dr. Herriot Tabuteau, CEO of Axsome Therapeutics.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss the topline SYMPHONY study results in narcolepsy.

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Neurology, Sleep, Depression, Somnolence, Deficit spending, Thomas Jefferson University, Partnership, Central nervous system, NT1, Cataplexy, Patient, CNS, Sleep disorder, Cognitive deficit, Ageing, EDS, Columbia, Anxiety, Hallucination, Narcolepsy Network, Epworth Sleepiness Scale, Life, Therapy, Sleep paralysis, ESS, Medical director, Idiopathic hypersomnia, FDA, Human, Nursing

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline results from the CRESCENDO (Characterizing Patient Perspectives on Unmet Needs in Narcolepsy) survey of patients with narcolepsy type 1 (NT1, i.e., narcolepsy with cataplexy) receiving treatment, demonstrating high rates of persistent symptoms and significant patient burden, despite being on current treatments. CRESCENDO was conducted in partnership with Narcolepsy Network, a national non-profit patient support organization for people with narcolepsy, idiopathic hypersomnia, and related sleep disorders.

Key Points: 
  • CRESCENDO was conducted in partnership with Narcolepsy Network, a national non-profit patient support organization for people with narcolepsy, idiopathic hypersomnia, and related sleep disorders.
  • All patients taking part in the survey were currently undergoing treatment for NT1.
  • The most common treatments were wake promoting agents (about 53% of surveyed patients), oxybates (47%), and stimulants (42%).
  • Axsome plans to present the detailed results of the CRESCENDO survey at upcoming scientific meetings.

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Monday, March 25, 2024
Therapy, Central nervous system, CNS, Rett syndrome, Conference, Schizophrenia, DSM-IV codes, Doctor of Philosophy

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024.

Key Points: 
  • NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024.
  • Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
  • A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com .
  • An archived edition of the session will be available later that day.

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Health, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • “The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, “We’re proud to be part of Gedeon Richter’s plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services.”

AVXL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corporation Class Action

Retrieved on: 
Thursday, March 21, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.
  • Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 13, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Retrieved on: 
Thursday, March 21, 2024
Week, Selective serotonin reuptake inhibitor, Data analysis, Post-traumatic stress disorder, Central nervous system, Patient, CNS, BNC210, Safety, DSM-5, FDA, PTSD, Pharmaceutical industry

ADELAIDE, Australia and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the release of the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder.

Key Points: 
  • In September 2023, Bionomics reported the topline results for the Phase 2b ATTUNE trial of BNC210 in patients with PTSD demonstrating that the trial met its primary endpoint and several secondary endpoints, and that BNC210 was generally well tolerated.
  • The full data analysis is detailed below and in an accompanying presentation of the results that is posted on the Company’s website .
  • “The full results of the ATTUNE Phase 2b trial further strengthen, the already compelling, topline results and position BNC210 as a potential highly differentiated treatment with rapid onset and durable efficacy that could improve outcomes for patients with PTSD.
  • Following the ATTUNE Phase 2b trial readout and based on a safety database of ~600 patients, BNC210 continues to demonstrate a non-sedating, non-habit forming, non-cognition impairing psychoactive profile.

SK Life Science Labs to Present Four Preclinical Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 21, 2024
Central nervous system, Information and communications technology, CNS, Research, Cancer, Abstract, AACR, IKZF2

KING OF PRUSSIA, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, today announced that four abstracts with preclinical data were accepted as poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held next month in San Diego.

Key Points: 
  • KING OF PRUSSIA, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, today announced that four abstracts with preclinical data were accepted as poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held next month in San Diego.
  • “The data SK Life Science Labs is presenting at AACR showcase the advances we are making on our molecular glue and heterobifunctional degrader pipeline,” said Zhihua Sui, Ph.D. Chief Scientific Officer, SK Life Science Labs.
  • “We are looking forward to attending this year’s meeting equipped with new data that show the potential of our advanced preclinical programs.
  • We are also looking forward to sharing important updates soon on SK Life Science Labs’ discovery efforts enabled by our proprietary MOPED™ molecular glue and targeted protein degradation platforms.”
    I.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, March 21, 2024
Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points: 
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.